ZURA BIO LIMITED Increase (Decrease) in Prepaid Expense
ZURA BIO LIMITED (ZURA) reported Increase (Decrease) in Prepaid Expense of -$403.19 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-28.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpense · last filed 2023-03-28
- ZURA BIO LIMITED increase (decrease) in prepaid expense for the quarter ending 2022-12-31 was -$102.50K.
- ZURA BIO LIMITED increase (decrease) in prepaid expense for the quarter ending 2022-09-30 was -$93.66K.
- ZURA BIO LIMITED increase (decrease) in prepaid expense for the quarter ending 2022-06-30 was -$101.34K.
- ZURA BIO LIMITED increase (decrease) in prepaid expense for the quarter ending 2022-03-31 was -$105.69K.
- ZURA BIO LIMITED increase (decrease) in prepaid expense for fiscal 2022 was -$403.19K.
| Period end | Increase (Decrease) in Prepaid Expense 3 month | Increase (Decrease) in Prepaid Expense 6 month | Increase (Decrease) in Prepaid Expense 7 month | Increase (Decrease) in Prepaid Expense 9 month | Increase (Decrease) in Prepaid Expense 10 month | Increase (Decrease) in Prepaid Expense 12 month |
|---|---|---|---|---|---|---|
| 2022-12-31 | -$102.50K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | -$196.16K derived: sum of 2 quarters · filed 2023-03-28 | -$297.50K derived: sum of 3 quarters · filed 2023-03-28 | -$403.19K 10-K · filed 2023-03-28 | ||
| 2022-09-30 | -$93.66K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$195.00K derived: sum of 2 quarters · filed 2022-11-14 | -$300.69K 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | -$101.34K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$207.03K 10-Q · filed 2022-08-12 | ||||
| 2022-03-31 | -$105.69K 10-Q · filed 2022-05-13 | |||||
| 2021-12-31 | $422.89K 10-K · filed 2023-03-28 | |||||
| 2021-09-30 | $531.25K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |